Myeloproliferative neoplasms (MPNs) are clonal disorders that share a common stem cell-derived clonal heritage but show a clear phenotypic diversity owing to differences in some underlying specific genetic rearrangements or mutations. 1 An increased number of circulating CD34 þ hematopoietic progenitors (CD34 þ PB) has been described in MPNs, with the highest concentrations observed in primary myelofibrosis (PMF). [2] [3] [4] Whether the quantity of this parameter can be taken as a measure of the proliferative potential of MPNs and thus the natural history and therapy outcome is still controversial. 5, 6 Since the introduction of allo-SCT as the only curative treatment modality for myelofibrosis, there is a growing interest to identify possible prognostic factors that may predict therapy outcome. Allo-SCT following reduced-intensity conditioning resulted in decreased TRM, and advanced age, HLA-mismatched donor 7 and absence of JAK2V617F mutation 8 were independently associated with inferior survival. This study aimed at exploring the potential value of CD34 þ PB as a biomarker for prognosis and follow-up in the allo-SCT setting.
Fifty-nine patients with PMF post-polycythemia vera/ essential thrombocythemia-myelofibrosis (PV/ET MF) who underwent allo-SCT after reduced-intensity conditioning in our institution between 27 July 2004 and 17 November 2009 and had a known CD34 þ PB value measured using flow cytometry prior to allo-SCT were evaluated. Patient characteristics are summarized in ) in 190 samples from healthy donors that were studied in parallel. There was no correlation between the estimated pre-allo-SCT CD34 þ PB and the following continuous parameters in the studied cohort: age (r ¼ À0.027, P ¼ 0.8), time from MPN diagnosis to allo-SCT (r ¼ À0.003, P ¼ 0.9), spleen size (r ¼ À0.027, P ¼ 0.8), percentage of circulating blasts (r ¼ þ 0.174, P ¼ 0.2) and JAK2V617F mutational allele burden (r ¼ 0.076, P ¼ 0.6). However, CD34
þ PB showed a weak but significant negative correlation with the time from diagnosis of myelofibrosis (or myelofibrotic transformation for post-PV/ET MF) to allo-SCT (r ¼ À0.287, P ¼ 0.03). The median CD34
þ PB did not differ in the studied cohort according to history of prior therapies (P ¼ 0.4), JAK2V617F mutation status (P ¼ 0.4), grade of reticulin fibrosis (P ¼ 0. 
value of pre-allo-SCT CD34 þ PB on therapy outcome. After a median follow-up of 11.9 months (range 1-76), preallo-SCT CD34 þ PB did not influence OS, disease-free survival (DFS) and cumulative incidence of relapse (REL) when evaluated as continuous parameters (P ¼ 0.2 for OS and DFS; P ¼ 0.7 for REL).
When comparing subgroups first according to the median value and then the percentiles, no significant difference was noted for OS and REL. However, DFS at 3 years was significantly different in the four percentiles (72, 37, 12 and 54%, respectively, P ¼ 0.05), where pairwise comparisons confirmed significant differences only between the first and second (P ¼ 0.02) and first and third (P ¼ 0.02) percentiles.
Second, we explored the value of post-allo-SCT CD34 þ PB for early prediction of REL. Overall, three hundred twenty-seven post-allo-SCT follow-up CD34
þ PB values were available. CD34 PB correlated with JAK2V617F allele burden (in the JAK2P617F-positive patients) (r ¼ þ 0.54, P ¼ 0.000) and to a lesser degree with donor chimerism (r ¼ À0.24, P ¼ 0.001).
Regular follow-ups of CD34 þ PB were available from 42 patients. Briefly, from 35 JAK2V617F-mutated patients, 19 reached molecular and clinical remission post-allo-SCT and remained so during the whole follow-up. In those patients, CD34
þ PB returned after allo-SCT to the normal range and stayed stable in the observation period. Eight other patients had, on the contrary, a minimal residual disease or molecular relapse after allo-SCT, but just in one of them elevated CD34
þ PB values were documented at the time of the molecular relapse episode. In line, while all remaining eight patients experienced a full-blown clinical relapse, only in two of them were CD34 þ PB levels elevated. This was in sharp contrast to the JAK2V617F mutation, which became readily detectable in all cases of clinical relapse. Of the seven patients without the JAK2V617F mutation, six were in clinical remission for the whole follow-up and had as well CD34
þ PB values within the normal range. Only one patient experienced a relapse that was accompanied by a significantly elevated CD34
þ PB value (Figure 1 ). The results of the current study do not support a potential predictive value of pre-allo-SCT CD34 þ PB for treatment outcome. First, no correlation with Lille and IPSS scoring systems, which have been shown previously to predict the outcome after allo-SCT, 7, 8 could be found. Second, evaluation of CD34 þ PB as a continuous variable and also based on median or percentiles did not result in any relevant outcome differences. þ PB returned to normal in all patients with clinical and molecular remission (n ¼ 25). At the same time, in only one out of eight patients with molecular relapse or minimal residual disease (MRD) and in three out of nine with clinical relapse was CD34 þ PB elevated. 
